Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer:

Background:More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance...